| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |